Sign in with Google
bearish
Celltrion (068270 KS): Muted Q1 2022 Performance Reflects Continuing Biosimilars Pricing Pressure
437 Views14 May 2022 10:20
SUMMARY
- Celltrion Inc (068270 KS) reported muted Q1 results, with revenue, operating profit, and net profit declining quarter-over-quarter. Its biosimilar products in the EU are facing price competition.
- Celltrion has recalled its COVID-19 rapid antigen test kits in the U.S. in April, which marks its third such recall in less than two months.
- Celltrion shares plunged 15% since I published bearish insight on the company on March 8. Bear thesis of biosimilar competition still holds good for the company.
Related Insights
More »Loading
Trending Collections
More »Trending Insights
More »- ASX200 (AS51 INDEX) Outlook: Rallying Out of a Bear Market Amid Passive Flows And Sector Strength
- Hyperscale Capex Is Maintained or Increased No Cuts or Postponement Capacity Constrain at AMZN GOOG
- Toyota Industries (6201) - Thinking About How To Value a ¥6trln Bid
- HEW: Good News From Less News
- Hainan Meilan Intl Airport (357 HK): Hainan SASAC's Left/Right Pocket MGO
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Discussions
(Paid Plans Only)
Top Quartile
Tina Banerjee
Global Healthcare Analyst
Price Chart(Sign Up to Access)
- Celltrion Siblings Announced Dividends: Trading Based on Past Patterns17 Dec 2022
- Celltrion Group Companies - Sharp Increase in Dividends16 Dec 2022
- Celltrion (068270 KS): Competition Makes US Approval of New Oncology Biosimilar Unappealing29 Sep 2022
- Celltrion (068270 KS): Muted Q1 2022 Performance Reflects Continuing Biosimilars Pricing Pressure14 May 2022
- Celltrion (068270 KS): Increasing Biosimilar Competition- Main Concerning Factor08 Mar 2022
- FSC Finally Reviews Accounting Fraud Allegations of Celltrion Group After 3 Years of Investigation23 Nov 2021
x